Research & Data
Industry news plus emerging therapeutic data and updates on research in dermatologyFrom the Blog
New Data for Dupixent Suggest Benefit for Chronic Spontaneous Urticaria, Bullous Pemphigoid
Data from two separate trial programs show that dupilimab (Dupixent, Sanofi-Aventis) met primary and secondary endpoints in the treatment of spontaneous urticaria (CSU) and bullous pemphigoid (BP). Regulatory filings for approval of Dupixent for CSU are expected, with...
White Blood Cell Disease Linked to Higher Melanoma Risk
Individuals with monoclonal B-cell lymphocytosis (MBL) have a 92% elevated risk of developing melanoma, new research shows. MBL, which has previously been shown to be a precursor to chronic lymphocytic leukemia (CLL), affects an estimated 8-10 million Americans over...
Positive Phase 2 Data for Verrica’s Investigational BCC Treatment
Results from the second part of a phase 2 open-label, multicenter, dose-escalation, proof-of-concept study suggest that VP-315 from Verrica Pharmaceuticals may be effective for the treatment of basal cell carcinoma. VP-315 is a potential first-in-class oncolytic...
Lower Levels of Certain Amino Acids Implicated in Chronic Pruritus
Recently identified low levels of metabolite biomarkers in blood plasma may contribute to symptoms of chronic pruritus of unknown origin (CPUO), new research suggests. For the study, published in Scientific Reports, University of Maryland School of Medicine...
FDA Approves Galderma’s Nemluvio for Prurigo Nodularis
Nemluvio (nemolizumab) from Galderma has been approved as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. The FDA decision comes after Nemluvio was granted Breakthrough Therapy Designation in December 2019 and Priority...